Behavioral Health Services of Virginia, Autism Services of Virginia, and VirtuAssist Announce Service Expansions and Program Updates
The Demario Adkins Podcast
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8668/262127_9061cd4454b91ad1_001full.jpg
Behavioral Health Services of Virginia (BHSVA)
Community-Based Mental Health Care Across Virginia
https://www.bhsva.net
BHSVA, a Medicaid-approved mental health agency, has expanded its mobile crisis response units and walk-in crisis care facilities in Richmond, Fredericksburg, and Tidewater. The agency provides trauma-informed and culturally responsive services, including:
Mental Health Skill-Building (MHSB)
Intensive In-Home Services (IIH)
24-Hour Crisis Stabilization & Mobile Crisis Response
Community Stabilization & Outpatient Therapy (Telehealth & In-Person)
The recent expansion aims to reduce emergency room visits and improve immediate access to mental health care.
Autism Services of Virginia (formerly Virginia ABA)
Applied Behavior Analysis (ABA) Therapy
https://www.autismservicesvirginia.com
Autism Services of Virginia has eliminated its waitlist for ABA therapy, increasing immediate availability for children with autism spectrum disorder. The organization offers:
Early Childhood Development & School Readiness Programs
Parent-Focused Training & Social Skills Development
Transportation Assistance for Families in Need
The clinic continues to expand its reach in underserved communities, with a focus on accessibility and timely care.
VirtuAssist
Virtual Staffing Solutions for Small Businesses
https://www.virtuassist.com
VirtuAssist, a virtual staffing agency serving over 1,000 businesses, has launched a new client portal integrating CRM systems for improved task tracking, communication, and performance management. The company has also introduced a $1 first-week trial and 50% off the remainder of the first month for new clients. Services include:
Executive Assistance & Administrative Support
Sales Outreach & Lead Generation
Customer Service & CRM Management
Bookkeeping and Invoicing
Planned Growth
Upcoming initiatives across the three organizations include:
Scaling mobile crisis care and 23-hour stabilization services in additional Virginia cities and into Texas.
Expanding ABA clinic locations and enhancing parent training programs.
Increasing VirtuAssist's service offerings to include full back-office solutions nationwide.
Learn More:
Contact:
Shazir Mucklai
shazir@imperium-pr.com
Imperium AI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Orthopedic Devices Market Poised for 4.78% CAGR Growth Through 2030: FDA Approvals, Breakthrough Device Designation and AI-Enabled Devices Reshape the Market
DelveInsight projects the orthopedic devices market to grow from USD 44.09B in 2023 to USD 57.79B by 2030 at a 4.78% CAGR, driven by rising musculoskeletal disorders and innovation. Key players include Stryker, Zimmer Biomet, Johnson & Johnson, Medtronic, Maxx Orthopedics, Hyalex Orthopaedics, and OrthoPreserve. FDA approvals, AI-enabled devices, and breakthrough technologies like OSCAR PRO, AccelStim, and UNID systems propel market expansion. DelveInsight's ' Orthopedic Devices - Global Market Insights, Competitive Landscape, and Market Forecast - 2030 ' report delivers a comprehensive analysis of the Orthopedic Devices market globally. Key Takeaways Market size projection: As per DelveInsight's analysis, the total market size of Orthopedic Devices globally is expected to surge from USD 44.09 billion in 2023 to USD 57.79 billion by 2030. Patient population data: The report provides the total musculoskeletal disease potential pool, highlighting that 1.71 billion people suffer from conditions such as osteoarthritis, osteoporosis, and rheumatoid arthritis globally, with 528 million osteoarthritis and 18 million rheumatoid arthritis cases in 2019, plus ~300K people living with spinal cord injuries. Key orthopedic device companies: Leading orthopedic device companies, such as Stryker Corporation, Zimmer Biomet, Johnson & Johnson, and Medtronic PLC Pipeline assets: Some of the key orthopedic device innovations in the pipeline include the OSCAR PRO ultrasonic arthroplasty revision system, AccelStim Bone Growth Stimulator, AxSOS Ankle Fusion System, Insignia Hip stem, and AI-enabled UNID spinal fusion devices. In August 2025, the FDA approved the SetPoint System, a neuroimmune modulation device for treating adults with moderately to severely active rheumatoid arthritis. In June 2025, Maxx Orthopedics received FDA 510(k) clearance for their Freedom® Total Knee System Titanium Tibial Base Plate. This approval introduces a new material option, transitioning from CoCrMo to Wrought Titanium-6Aluminium-4Vanadium ELI Alloy (Ti6Al4V ELI) for the tibial base plate component. In May 2025, Hyalex Orthopaedics secured FDA approval of its supplemental Investigational Device Exemption (IDE) application for the Freestyle Knee Implant. In March 2025, Johnson & Johnson MedTech showcased major advances at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting. Building on their momentum from the previous year's 18 FDA 510(k) clearances and 45 global product launches, the company introduced cutting-edge implants, advanced techniques, and data-driven technologies across joint reconstruction, trauma, extremities, and spine specialties. January 2025: OrthoPreserve received Breakthrough Device Designation and enrolled in the FDA TAP program for its Defender meniscus replacement implant. Discover recent advancements in the Orthopedic Devices landscape @ Orthopedic Devices Recent Developments. Orthopedic Devices Market Dynamics The global orthopedic devices market reached USD 44.09 billion in 2023 and is expanding at a compound annual growth rate (CAGR) of 4.78%, projected to attain USD 57.79 billion by 2030. This growth reflects both demographic pressures, an aging population with 54.1 million U.S. residents aged 65 or older as of 2019, and the rising incidence of bone and joint disorders. Musculoskeletal conditions are the leading contributors to disability worldwide, driving substantial demand for implants, supports, and related devices. Orthopedic devices market drivers include the increasing prevalence of osteoarthritis (528 million cases) and osteoporosis, occupational and non-occupational injuries, and technological innovation in implant materials and design. Innovations such as biocompatible titanium constructs and AI-integrated hardware are elevating clinical outcomes and reducing complication rates. For instance, ultrasonic arthroplasty tools like OSCAR PRO facilitate minimally invasive revisions, while AccelStim enhances fracture healing through targeted bone stimulation. The advances in biomechanics, materials science, and regenerative engineering underpin device performance. Titanium interbody cages, porous polymer composites, and smart sensors are enabling load-sharing implants with real-time monitoring. Mechanistically, bone growth stimulators exploit electromagnetic or ultrasonic energy to upregulate osteoblast activity and accelerate fusion. The orthopedic devices innovation and development is robust, with numerous devices in various trial phases. OrthoPreserve's Defender meniscus replacement is in breakthrough designation pathways, and Medtronic's UNID system illustrates the integration of AI in device-guided spinal fusion. Concurrently, Stryker and Zimmer Biomet are conducting post-market surveillance studies to refine long-term safety profiles. The orthopedic devices competitive landscape features diversified strategies: major players invest in in-licensing and partnerships to expand portfolios, while mid-sized innovators focus on niche applications such as ankle and wrist arthrodesis. Strategic M&A activity is anticipated as companies seek to consolidate capabilities in biologics-enabled devices. The orthopedic devices market barriers include regulatory hurdles for novel biomaterials, reimbursement constraints, and potential competition from non-implant therapies (e.g., biologics, cell therapy). However, opportunities abound in emerging markets, tele-enabled surgery, and personalized implant design via 3D printing. The future outlook projects continued growth driven by demographic trends, rising healthcare expenditure, and sustained R&D investment in next-generation orthopedic solutions. Download the Orthopedic Devices Market report to understand which factors are driving the therapeutic market @ Orthopedic Devices Market Trends. Orthopedic Devices Potential Patient Pool Musculoskeletal disorders impact 1.71 billion individuals globally, with 528 million suffering from osteoarthritis and 18 million affected by rheumatoid arthritis as of 2019. Spinal cord injuries afflict approximately 296,000 patients worldwide, with 17,900 new cases annually. DelveInsight's epidemiology segmentation reveals that osteoarthritis accounts for the largest share of years lived with disability, followed by rheumatoid arthritis. The total orthopedic devices eligible patient pools encompass those requiring surgical implants or supportive orthoses, with treated cases driven by healthcare access and device availability. Geographic analysis indicates North America leads market adoption, followed by Europe and Asia-Pacific, where aging demographics and expanding surgical capacity fuel device uptake. Forecasting through 2030 anticipates rising incident cases and an expanding treated cohort as minimally invasive and outpatient surgical centers proliferate. Discover evolving trends in the Orthopedic Devices patient pool forecasts @ Orthopedic Devices Patient Pool Analysis. Key Orthopedic Devices Companies and Competitive Landscape The orthopedic devices sector is anchored by established players and dynamic innovators. Current treatment options range from prophylactic supports (braces, orthoses) to complex implants (total joint prostheses, spinal fusion systems). Stryker Corporation leads with its Insignia Hip stem and AxSOS Ankle Fusion System, leveraging titanium design and updated screw arrays to improve fusion rates. Zimmer Biomet's portfolio includes knee and shoulder implants, while Johnson & Johnson focuses on advanced soft-tissue fixation devices. Medtronic's UNID rods and screws incorporate AI algorithms to optimize spinal alignment intraoperatively. Orthopedic devices development activity features OrthoPreserve's Defender meniscus replacement entering pivotal trials under FDA Breakthrough Device designation and Orthofix's AccelStim in post-approval studies. Key partnerships include licensing agreements for biomaterial coatings and co-development of sensor-enabled implants. Market positioning emphasizes value-based outcomes, with companies forging payor contracts that reward reduced revision rates. Recent milestones encompass FDA clearances (AccelStim May 2022, UNID June 2021), AAOS product launches (Insignia March 2022), and strategic collaborations in 3D-printed implant manufacturing. Commercial arrangements involve joint ventures in emerging markets to enhance distribution networks. Collectively, these efforts define a competitive environment focused on enhancing patient outcomes, expanding indications, and driving long-term growth in the orthopedic devices landscape. Delve deeper into the major and specialised companies in the Orthopedic Devices market @ Orthopedic Devices Competitive Landscape. Conclusion The orthopedic devices market is poised for sustained expansion through 2030, driven by demographic imperatives, technological innovation, and a diversified competitive field. Strategic collaborations, regulatory breakthroughs, and evolving clinical practices will shape the future, ensuring that next-generation implants and support devices meet the growing global demand for improved musculoskeletal health. Table of Contents 1. Orthopedic Devices Market Report Introduction 2. Orthopedic Devices Market Executive Summary 3. Competitive Landscape 4. Regulatory Analysis 5. Orthopedic Devices Market Key Factors Analysis 6. Orthopedic Devices Market Porter's Five Forces Analysis 7. Orthopedic Devices Market Assessment 8. Orthopedic Devices Market Company and Product Profiles 9. KOL Views 10. Project Approach 11. About DelveInsight 12. Disclaimer & Contact Us About DelveInsight DelveInsight is a leading business consulting and market research company focused on the healthcare and life sciences sectors, providing comprehensive market intelligence, competitive landscape analysis, and strategic insights to support decision-making across the pharmaceutical industry. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
CTV News
6 hours ago
- CTV News
Rabbits with ‘horns' in Colorado are being called ‘Frankenstein bunnies.' Here's why
This photo provided by the Iowa Department of Natural Resources shows a deceased Eastern cottontail rabbit infected with Shope papillomavirus in October 2021. (Iowa Department of Natural Resources via AP) DENVER — A group of rabbits in Colorado with grotesque, horn-like growths may seem straight out of a low-budget horror film, but scientists say there's no reason to be spooked — the furry creatures merely have a relatively common virus. The cottontails recently spotted in Fort Collins are infected with the mostly harmless Shope papillomavirus, which causes wart-like growths that protrude from their faces like metastasizing horns. Viral photos have inspired a fluffle of unflattering nicknames, including 'Frankenstein bunnies,' 'demon rabbits' and 'zombie rabbis.' But their affliction is nothing new, with the virus inspiring ancient folklore and fueling scientific research nearly 100 years ago. The virus likely influenced the centuries-old jackalope myth in North America, which told of a rabbit with antlers or horns, among other animal variations. The disease in rabbits also contributed to scientists' knowledge about the connection between viruses and cancer, such as the human papillomavirus that causes cervical cancer. The virus in rabbits was named after Dr. Richard E Shope, a professor at The Rockefeller University who discovered the disease in cottontails in the 1930s. News about the rabbit sightings in Fort Collins, 65 miles (105 kilometres) north of Denver, started getting attention after residents started spotting them around town and posting pictures. Kara Van Hoose, a spokesperson for Colorado Parks and Wildlife, told The Associated Press on Wednesday that the agency has been getting calls about the rabbits seen in Fort Collins. But she said that it's not uncommon to see infected rabbits, especially in the summer, when the fleas and ticks that spread the virus are most active. The virus can spread from rabbit to rabbit but not to other species, including humans and pets, she said. The growths resemble warts but can look like horns if they grow longer, Van Hoose said. The growths don't harm rabbits unless they grow on their eyes or mouths and interfere with eating. Rabbits' immune systems are able to fight the virus and, once they do, the growths will disappear, she said. Finley reported from Norfolk, Virginia. Ben Finley And Colleen Slevin, The Associated Press
Globe and Mail
7 hours ago
- Globe and Mail
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2025, and is pleased to provide an update on key business milestones. 'With our recently announced funding agreement in place, we are well positioned to continue advancing our lead clinical programs, CYB003 and CYB004, through multiple inflection points,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Gaining European CTA approval and MHRA approval to commence EMBRACE in the UK has enabled us to expand our multinational Phase 3 PARADIGM program evaluating CYB003 for the potential adjunctive treatment of major depressive disorder. PARADIGM is a significantly larger program than the completed Phase 2 study, with anticipated combined enrollment of approximately 550 participants. Our Phase 3 studies will evaluate the potential clinical benefits of CYB003 in patients living with moderate to severe MDD, and whose symptoms are uncontrolled with existing antidepressant treatment. Our Phase 2 study evaluating CYB004 in generalized anxiety disorder is expected to complete patient enrollment this month.' 'Cybin is in a strong position to advance our programs and continue our work to deliver innovative therapies to address some of the most challenging mental health disorders we face today and is helping to build momentum across the sector - both from a clinical and regulatory perspective,' concluded Drysdale. Recent Business and Pipeline Highlights: Received European approval and MHRA approval for EMBRACE, the second Phase 3 study within the PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD, on schedule. The Company has received CTA approval from the Irish Medicines Board for the EMBRACE study in Ireland, Poland, and Greece, as well as approval from the MHRA. EMBRACE is a 12-week, randomized, double-blind, placebo-controlled study in 330 participants with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but with inadequate response. EMBRACE will evaluate two doses of CYB003 (8 mg, 16 mg) three weeks apart, compared to an inactive placebo. The primary endpoint is change in depressive symptoms as measured by the change in MADRS from baseline six weeks after the first dose. Making strong progress on CYB003 development through the APPROACH and EXTEND studies. Dosing is currently ongoing in the first pivotal study, APPROACH, which is expected to enroll 220 patients across 45 U.S. clinical sites. We are pleased to report that patient rollovers continue into EXTEND, the long-term extension study. Clinical Program Summary CYB003: Deuterated psilocin program Phase 3 PARADIGM program is underway, with topline data from first pivotal study, APPROACH, expected in 2026 1. CYB003 program accomplishments: Received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD. A completed Phase 2 study of CYB003 in MDD demonstrated durability of effect at 12 months: 100% of participants receiving two doses of 16 mg were responders. 71% of participants receiving two doses of 16 mg were in remission. Mean change from baseline in MADRS was approximately -23 points after two 16 mg doses. CYB004: Deuterated dimethyltryptamine program The Phase 2 CYB004 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with generalized anxiety disorder, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed. Patient enrollment is expected to be completed this month 1. Change in Presentation Currency Effective April 1, 2025, the Company changed its presentation currency from the Canadian dollar to the United States dollar (' USD '). The change in presentation currency was made to better reflect the Company's operations, align with the currency in which the majority of cash-based expenses are denominated, and improve comparability of its financial results with other publicly traded businesses in the industry. As a result, all amounts presented in this press release are in USD unless otherwise stated. First-Quarter Financial Highlights Cash totaled $118.7 million as of June 30, 2025. Net loss was $24.6 million for the quarter ended June 30, 2025, compared to a net loss of $10.8 million in the same period last year. Cash-based operating expenses consisting of research, general, and administrative costs totaled $23.9 million for the quarter ended June 30, 2025, compared to $11.9 million, in the same period last year. Cash flows used in operating activities were $29.5 million for the quarter ended June 30, 2025, compared to $19.9 million in the same period last year. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Note: There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia; the Company's expectation to enroll 220 participants at approximately 45 clinical sites across the United States for the APPROACH study; the Company's expectation to complete enrollment in CYB004 Phase 2 study in August 2025; the Company's expectation to receive topline data from APPROACH in 2026; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2025, and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
